{"id":5657,"date":"2013-02-25T09:56:50","date_gmt":"2013-02-25T13:56:50","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=5657"},"modified":"2013-02-25T09:56:50","modified_gmt":"2013-02-25T13:56:50","slug":"kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657","title":{"rendered":"Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG &#038; IMGN"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 02\/25\/2013 (wallstreetpr) &#8211; Roche Holding Ltd (VTX: ROG) in partnership with ImmunoGen, Inc (NASDAQ:IMGN has created an anti-cancer therapy that has gained approval from the U.S Food Drug Administration. The drug which was originally called T-DM1 will now be sold under the brand name Kadcyla as it has received clearance for treating humans who suffer from Her2(positive metastatic breast cancer). The therapy is a combination of the anti-cancer drug manufactured by Roche Holding Ltd (VTX: ROG) and technology from ImmunoGen, Inc (NASDAQ:IMGN)\u2019s.<\/p>\n<p style=\"text-align: justify;\"><b>Killing cancer cells and boosting company growth<\/b><\/p>\n<p style=\"text-align: justify;\">This therapy ensures that the drug bypasses healthy cells and carries the chemotherapy straight to the malignant ones. ImmunoGen, Inc (NASDAQ:IMGN) announced that its U.S approval will earn it $10.5 million. According to a market analyst, this high-potential drug is expected to generate over $5 billion of worldwide sales. Sandra Horning, head of global oncology at the Switzerland-based Roche Holding Ltd (VTX: ROG) said that the therapy is a super-Herceptin of sorts. Another important plus is that the drug has fewer side-effects when compared to other existing therapies.<\/p>\n<p style=\"text-align: justify;\"><b>Herceptin before Kadcyla<\/b><\/p>\n<p style=\"text-align: justify;\">Kadcyla will be launched in the U.S within a fortnight but the FDA has said that patients should first try Herceptin treatment before moving onto Kadcyla, both of which are\u00a0 Roche Holding Ltd (VTX:ROG) products. The cost of the Kadcyla treatment will amount to $9800 per month and will have to continue for 9.6 months taking its cost to $94,000 for the entire course. Roche Holding Ltd (VTX: ROG), the worlds largest manufacturer of tumor medication is testing the same drug as a first-line treatment for women who suffer from spreading (metastatic) breast cancer. ImmunoGen, Inc (NASDAQ:IMGN) will be receiving between 3 percent- 7 percent in royalties and its worldwide collections from royalties could be to the tune of $350 million by 2025. T-DM1 prevents the growth of new cancer cells and the DM1 release destroys them and the approval of this drug has opened up a host of possibilities in the treatment of cancer.<\/p>\n<p style=\"text-align: justify;\">Shares of ImmunoGen, Inc (NASDAQ:IMGN) went up by 1.89% to close at $14.57<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 02\/25\/2013 (wallstreetpr) &#8211; Roche Holding Ltd (VTX: ROG) in partnership with ImmunoGen, Inc (NASDAQ:IMGN has created an anti-cancer therapy that has gained approval [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":5659,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[265],"tags":[1764,1765,1738,1739],"stock_ticker":[],"class_list":["post-5657","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-international","tag-immunogen-inc-nasdaqimgn","tag-nasdaqimgn","tag-roche-holding-ltd-vtxrog","tag-vtxrog","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG &amp; IMGN - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG &amp; IMGN - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 02\/25\/2013 (wallstreetpr) &#8211; Roche Holding Ltd (VTX: ROG) in partnership with ImmunoGen, Inc (NASDAQ:IMGN has created an anti-cancer therapy that has gained approval [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-02-25T13:56:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/02\/PC032601-1024x768.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Van Bettauer\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Van Bettauer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657\"},\"author\":{\"name\":\"Van Bettauer\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\"},\"headline\":\"Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG &#038; IMGN\",\"datePublished\":\"2013-02-25T13:56:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657\"},\"wordCount\":360,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/02\/PC032601-1024x768.jpg\",\"keywords\":[\"ImmunoGen Inc (NASDAQ:IMGN)\",\"NASDAQ:IMGN\",\"Roche Holding Ltd (VTX:ROG)\",\"VTX:ROG\"],\"articleSection\":[\"International\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657\",\"name\":\"Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG & IMGN - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/02\/PC032601-1024x768.jpg\",\"datePublished\":\"2013-02-25T13:56:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/02\/PC032601-1024x768.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/02\/PC032601-1024x768.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG &#038; IMGN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\",\"name\":\"Van Bettauer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"caption\":\"Van Bettauer\"},\"description\":\"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG & IMGN - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657","og_locale":"en_US","og_type":"article","og_title":"Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG & IMGN - Wall Street PR","og_description":"Boston, MA 02\/25\/2013 (wallstreetpr) &#8211; Roche Holding Ltd (VTX: ROG) in partnership with ImmunoGen, Inc (NASDAQ:IMGN has created an anti-cancer therapy that has gained approval [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-02-25T13:56:50+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/02\/PC032601-1024x768.jpg","type":"image\/jpeg"}],"author":"Van Bettauer","twitter_misc":{"Written by":"Van Bettauer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657"},"author":{"name":"Van Bettauer","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d"},"headline":"Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG &#038; IMGN","datePublished":"2013-02-25T13:56:50+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657"},"wordCount":360,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/02\/PC032601-1024x768.jpg","keywords":["ImmunoGen Inc (NASDAQ:IMGN)","NASDAQ:IMGN","Roche Holding Ltd (VTX:ROG)","VTX:ROG"],"articleSection":["International"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657","url":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657","name":"Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG & IMGN - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/02\/PC032601-1024x768.jpg","datePublished":"2013-02-25T13:56:50+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/02\/PC032601-1024x768.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/02\/PC032601-1024x768.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kadcyla-from-roche-and-immunogen-wins-fda-thumbs-up-rog-imgn-5657#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG &#038; IMGN"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d","name":"Van Bettauer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","caption":"Van Bettauer"},"description":"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/5657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=5657"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/5657\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/5659"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=5657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=5657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=5657"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=5657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}